{"filing":{"accession_number":"0001193125-26-343479","cik":"0001691082","ticker":"LBRX","company_name":"LB PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"d303033d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/d303033d8k.htm"},"events":[{"id":26907,"run_id":24474,"accession_number":"0001193125-26-343479","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"LB Pharmaceuticals issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The disclosure includes quarterly R\u0026D expenses ($44.1M vs. $2.4M prior year), G\u0026A expenses ($9.8M vs. $2.4M), and net loss ($51.6M vs. $4.9M), along with cash position and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28202,"accession_number":"0001193125-26-343479","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The disclosure includes quarterly R\u0026D expenses ($44.1M vs. $2.4M prior year), G\u0026A expenses ($9.8M vs. $2.4M), and net loss ($51.6M vs. $4.9M), along with cash position and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:06:57.887088+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28202,"accession_number":"0001193125-26-343479","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LB Pharmaceuticals issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The disclosure includes quarterly R\u0026D expenses ($44.1M vs. $2.4M prior year), G\u0026A expenses ($9.8M vs. $2.4M), and net loss ($51.6M vs. $4.9M), along with cash position and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:06:57.887088+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-08-11"}]}